Delisting risk
GUTS · NASDAQ · Biotechnology

Fractyl Health (GUTS)

Develops clinical-stage therapies for obesity and type 2 diabetes through the gut and pancreas.

$0.7077
Pre-market−0.00 (−0.03%)
At close$0.7079(−0.03%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.13
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.52−$0.49−$0.53−$0.35$0.15−$0.13−$0.12Pending
Estimate−$0.44−$0.49−$0.37−$0.34−$0.19−$0.17−$0.14−$0.13
Surprise−18.2%0.0%−43.2%−2.9%+178.9%+23.5%+11.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$3.0KPending
Estimate$10.0K
Surprise−70.0%

History

DateEstimateReportedSurprise
Nov 2026−$0.13
Aug 2026−$0.14−$0.12+11.1%
May 2026−$0.17−$0.13+23.5%
Mar 2026−$0.19$0.15+178.9%
Nov 2025−$0.34−$0.35−2.9%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Dec 2021
Sep 2021
Dec 2020
Sep 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.13
Aug 10, 2026−$0.14−$0.12+11.1%+4.0%
May 12, 2026−$0.17−$0.13+23.5%+29.2%
Mar 24, 2026−$0.19$0.15+178.9%+16.2%
Nov 12, 2025−$0.34−$0.35−2.9%−0.9%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 13, 2025
Mar 3, 2025
Nov 12, 2024
Aug 14, 2024
May 13, 2024
Apr 1, 2024
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 30, 2022
Sep 30, 2022
Dec 30, 2021
Sep 29, 2021
Dec 30, 2020
Sep 29, 2020